Login to Your Account

Merck Stops Work On Pain Drug Garnered From Neuromed Deal

By Randall Osborne

Thursday, August 9, 2007
Merck & Co. Inc.'s decision to back away from the Phase II-stage, N-type calcium channel blocker NMED-160 for pain leaves intact its collaboration with privately held Neuromed Pharmaceuticals Inc., and the companies plan to keep working in the same pathway to find another compound. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription